MRI-guided risk stratification for neoadjuvant immunotherapy in rectal cancer - Top-Institutions - MDSpire

MRI-guided risk stratification for neoadjuvant immunotherapy in rectal cancer

  • By

  • Jiali Zhang

  • Feng Tian

  • Yue Shang

  • Honghai Dai

  • Shuo Zhang

  • Bing Kang

  • Jiaxiang Xin

  • Ximing Wang

  • Changqing Jing

  • Cong Sun

  • May 29, 2026

  • 0 min

Share

Top Institutions in Oncology

Brief introduction explaining scope and methodology.

  • #1

    Memorial Sloan Kettering Cancer Center
    Memorial Sloan Kettering Cancer Center

    New York, NY

    Key Differentiators

    • Oncology
    • Colorectal Surgery
    • Radiology

  • #2

    The University of Texas MD Anderson Cancer Center
    The University of Texas MD Anderson Cancer Center

    Houston, TX

    Key Differentiators

    • Oncology
    • Radiation Oncology
    • Surgical Oncology

  • #3

    Helsinki University Hospital
    Helsinki University Hospital

    Helsinki, Finland

    Key Differentiators

    • Oncology
    • Surgical Oncology

  • #4

    Cancer Hospital, Chinese Academy of Medical Sciences
    Cancer Hospital, Chinese Academy of Medical Sciences

    Beijing, China

    Key Differentiators

    • Oncology
    • Surgical Oncology

  • #5

    University Hospital “Luigi Vanvitelli”
    University Hospital “Luigi Vanvitelli”

    Naples, Italy

    Key Differentiators

    • Oncology
    • Surgical Oncology

Original Source(s)

MRI-guided risk stratification for neoadjuvant immunotherapy in rectal cancer

  • by Jiali Zhang, Feng Tian, Yue Shang, Honghai Dai, Shuo Zhang, Bing Kang, Jiaxiang Xin, Ximing Wang, Changqing Jing, Cong Sun

  • May 29, 2026

Related Content

Evolution of therapeutic paradigms in Hodgkin lymphoma: from “cure-oriented” to “functional cure”

Lifestyle and Surveillance Adherence After Childhood Cancer—When Financial Hardship Shapes Survivorship

Lenvatinib induces ferroptosis-related changes in osteosarcoma cells involving the p-STAT3/p53/xCT axis